A recent retrospective cohort study looked at GLP-1 adherence in patients with obesity and with/without diabetes: Those with T2DM: 46.5% discontinued by year one 64.1% discontinued by year two Those without T2DM: 64.8% discontinued by year one 84.4% discontinued by year two So yes access is a problem
Methionine, choline, and inositol function as methyl donors that optimize VLDL export from the liver, preventing the fat accumulation that slows metabolic throughput during extended caloric deficits
Other natural compounds, including hyperoside, loganin, honokiol, and pyrroloquinoline quinone, have also been shown to alleviate renal damage in DKD by suppressing TEC pyroptosis (172175)
If so, this should be done under careful medical supervision and monitoring by your healthcare provider
Mice then received an intraperitoneal bolus of 2 mg/g D-Glucose (Sigma-Aldrich) for glucose tolerance tests (GTT), 0.75 IU/kg of human insulin (Actrapid 100 IU/mL, Novo Nordisk) for insulin tolerance tests (ITT) or 2 g/kg pyruvate (Sigma-Aldrich) for pyruvate tolerance tests (PTT) as in (20)
However, it can occur indirectly due to side effects like nausea, bloating, or increased anxiety, especially when adjusting to the medication